<DOC>
	<DOCNO>NCT00310544</DOCNO>
	<brief_summary>The purpose study determine dose drug effective delineation dead heart muscle .</brief_summary>
	<brief_title>Depiction Delayed Enhancement Patients With Documented Myocardial Infarction</brief_title>
	<detailed_description>This study previously post Berlex , Inc. Berlex , Inc. rename Bayer HealthCare Pharmaceuticals , Inc.Bayer HealthCare Pharmaceuticals , Inc.is sponsor trial .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<criteria>At least 8 week postdocumented myocardial infarction ( heart attack ) History radiation therapy chest Clinically unstable Any contraindication MRI</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>